Politics

EMAUKEU

EMA prepares new system for detecting adverse drug reactions

06.03.2012 - The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance measures to give every patient living in an EU member state the chance to report adverse drug reactions (ADRs) to their respective national regulatory authority.

An information campaign on direct reporting will be launched by the EMA and member states later this year. Preparations to implement the new pharmacovigilance rules (Regulation (EU) No 1235/2010 and Directive 2010/84/EU – adopted in December 2010) will begin in mid-July. The new rules will create many additional documentation tasks for drug developers and the Agency. 
Up to now, the EMA has focussed its post-marketing drug safety monitoring on the 568 centrally-authorised medicines for human use. But starting this year, the EU drug watchdog will step-by-step also include pharmacovigilance data from nationally authorised medicines. The London-based drug experts estimate the new responsibility will mean having to cope with at least 80,000 additional ADR reports per year. About 3,000 analyses will come in from the detection of new safety signals from EU-approved medicines, while a further 624 post-marketing safety studies per year will have to be assessed. 

“New rules governing the monitoring, identification and assessment of adverse events caused by pharmaceuticals will be launched in Europe in July 2012,” announced the EMA. A new committee named PRAC (Pharmacovigilance Risk Assessment Committee) will be responsible for the implementation of the new drug safety rules – and it has an ambitious working plan. First of all, PRAC will implement a procedure for protocol approval of safety studies on drugs that have already been approved at the EU level. Second, the committee will establish a process for the coordination of pharmaco­vigilance inspect­ions. Third, it will revise the process for the detection of adverse drug signals so that data inputs from nationally approved medicines can be included. 
Following meetings with the industry, the EMA is expected to publish details soon on the requirements for the electronic submission of a revised pharmaco­vigilance system master file. However, electronic submission of the safety data will have to be in place by 2015 at the latest. Until detailed guidance from PRAC is available, the EMA has published provisional information to help companies navigate through the new rules (“Information on transitional arrangements for pharmacovigilance legislation”). Additionally, the EMA published a draft concept paper defining Good Pharmacovigilance Practice (GVP).

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR243.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.3%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.72 EUR-28.0%
  • PROSENSA (NL)9.67 USD-23.4%
  • PROTHENA PLC (IE)17.79 USD-21.1%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP656.1%
  • PAION (D)2.42 EUR272.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • PROSENSA (NL)9.67 USD-70.9%

No liability assumed, Date: 31.07.2014